NASDAQ: LIVNLivanova PLC Stock
$45.76-0.87 (-1.87%)
Updated Jun 13, 2025
LIVN Price
$45.76
Fair Value Price
$15.02
Market Cap
$2.50B
52 Week Low
$32.48
52 Week High
$57.35
P/E
-11.24x
P/B
2.41x
P/S
1.68x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.28B
Earnings
-$222.15M
Gross Margin
69.3%
Operating Margin
-10.25%
Profit Margin
-17.4%
Debt to Equity
1.47
Operating Cash Flow
$197M
Beta
0.9
Next Earnings
Jul 29, 2025
Ex-Dividend
N/A
Next Dividend
N/A
LIVN Overview
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine LIVN's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
LIVN
Ranked#17 of 108
Ranked#17 of 108
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $29.39 | A | |
| $12.10 | A | |
| $20.07 | A |
Be the first to know about important LIVN news, forecast changes, insider trades & much more!
LIVN News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how LIVN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LIVN ($45.76) is overvalued by 204.74% relative to our estimate of its Fair Value price of $15.02 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
LIVN ($45.76) is not significantly undervalued (204.74%) relative to our estimate of its Fair Value price of $15.02 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
LIVN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LIVN due diligence checks available for Premium users.
Valuation
LIVN fair value
Fair Value of LIVN stock based on Discounted Cash Flow (DCF)
Price
$45.76
Fair Value
$15.02
Overvalued by
204.74%
LIVN ($45.76) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LIVN ($45.76) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LIVN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LIVN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-11.24x
Industry
35.6x
Market
31.36x
LIVN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.41x
Industry
3.99x
LIVN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LIVN's financial health
Profit margin
Revenue
$316.9M
Net Income
-$327.3M
Profit Margin
-103.3%
LIVN's Earnings (EBIT) of -$130.69M... subscribe to Premium to read more.
Interest Coverage Financials
LIVN's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$2.6B
Liabilities
$1.5B
Debt to equity
1.47
LIVN's short-term assets ($1.17B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LIVN's short-term assets ($1.17B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LIVN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
LIVN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$24.0M
Investing
-$10.6M
Financing
-$4.4M
LIVN's operating cash flow ($197.02M)... subscribe to Premium to read more.
Debt Coverage Financials
LIVN vs Medical Device Stocks
Livanova Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.